A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in Biological Psychiatry
- Vol. 53 (2) , 136-143
- https://doi.org/10.1016/s0006-3223(02)01454-3
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Selegiline and Other Atypical Monoamine Oxidase Inhibitors in DepressionPsychiatric Annals, 2001
- Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of EuphoriaNeuropsychopharmacology, 1999
- Statistics Notes: Survival probabilities (the Kaplan-Meier method)BMJ, 1998
- Major depression following smoking cessationAmerican Journal of Psychiatry, 1997
- The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice GuidelineJAMA, 1996
- Inhibition of monoamine oxidase B in the brains of smokersNature, 1996
- Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disordersPharmacology & Therapeutics, 1996
- A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*Clinical Pharmacology & Therapeutics, 1995
- Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawalSynapse, 1994
- Doxepin as an adjunct to smoking cessation: a double-blind pilot studyAmerican Journal of Psychiatry, 1989